<DOC>
	<DOC>NCT00321464</DOC>
	<brief_summary>The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.</brief_summary>
	<brief_title>A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Adults with histologically or cytologically confirmed breast adenocarcinoma radiographic evidence of at least one bone mets Easter Cooperative Oncology Group status of 0, 1 or 2; adequate organ function Current or prior IV bisphosphonate administration current or prior oral bisphosphonates for bone mets life expectancy of less than 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fractures</keyword>
	<keyword>Compressions</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Bone metastases</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Skeletal</keyword>
	<keyword>Radiation</keyword>
	<keyword>Surgery to Bone</keyword>
</DOC>